Table 4.

Baseline characteristics of patients stratified by new risk stratification.

Characteristic	Low-riskgroup (n = 88)	Intermediate-risk group (n = 38)	High-risk group (n = 126)	P
Age				0.751
≤60	44 (50.0%)	19 (50.0%)	69 (54.8%)
>60	44 (50.0%)	19 (50.0%)	57 (45.2%)
Gender				0.165
Male	76 (86.4%)	30 (78.9%)	114 (90.5%)
Female	12 (13.6%)	8 (21.1%)	12 (9.5%)
KPS				0.083
≥90	53 (60.2%)	26 (68.4%)	94 (74.6%)
<90	35 (39.8%)	12 (31.6%)	32 (25.4%)
Weight loss				0.127
Yes	27 (30.7%)	10 (26.3%)	52 (41.3%)
No	61 (69.3%)	28 (73.7%)	74 (58.7%)
Pain of chest and back				0.441
Yes	14 (15.9%)	8 (21.1%)	29 (23.0%)
No	74 (84.1%)	30 (78.9%)	97 (77.0%)
Tumor location				0.033
Cervical	7 (8.0%)	4 (10.5%)	11 (8.7%)
Upper thoracic	36 (40.9%)	16 (42.1%)	26 (20.6%)
Middle thoracic	28 (31.8%)	12 (31.6%)	53 (42.1%)
Lower thoracic	17 (19.3%)	6 (15.8%)	36 (28.6%)
Clinical T stage, 8th				<0.001
T1	7 (8.0%)	0 (0.0%)	2 (1.6%)
T2	12 (13.6%)	0 (0.0%)	4 (3.2%)
T3	69 (78.4%)	0 (0.0%)	70 (55.6%)
T4	0 (0.0%)	38 (100.0%)	50 (39.7%)
Clinical N stage, 8th				<0.001
N0	37 (42.0%)	21 (55.3%)	1 (0.8%)
N1	40 (45.5%)	10 (26.3%)	36 (28.6%)
N2	9 (10.2%)	3 (7.9%)	65 (51.6%)
N3	2 (2.3%)	4 (10.5%)	24 (19.0%)
GTVnd				<0.001
≥4.35	0 (0.0%)	0 (0.0%)	126 (100.0%)
<4.35	88 (100.0%)	38 (100.0%)	0 (0.0%)
Tumor length, cm				0.211
≤6	49 (55.7%)	21 (55.3%)	56 (44.4%)
>6	39 (44.3%)	17 (44.7%)	70 (55.6%)
Radiation dose, Gy				0.397
<54	26 (29.5%)	8 (21.1%)	41 (32.5%)
≥54	62 (70.5%)	30 (78.9%)	85 (67.5%)
Consolidation chemotherapy				0.174
Yes	33 (37.5%)	21 (55.3%)	52 (41.3%)
No	55 (62.5%)	17 (44.7%)	74 (58.7%)